We are pleased to welcome Tissue Regenix Group Ltd (TRX) to the platform and announce its admission to the Asset Match Private Market.

Tissue Regenix Group Ltd is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

The first auction in the Ordinary Shares is scheduled to take place on Tuesday 24 February 2026, subsequent auctions are to take place on a quarterly basis thereafter. All relevant company and auction information can be found on the company page here.

For details on how to participate please refer to the auction instructions or alternatively contact dealing@assetmatch.com or Tel 020 7248 2788.

If you wish to receive auction and company updates, please register on www.assetmatch.com and add Tissue Regenix Group to your Watchlist.